Quantitative assessment of mRNA TGF-β1 in liver tissue in connection with serum mean daily level of TGF-β1 in chronic hepatitis B patients;Ocena ilościowa mRNA TGF-β1 w bioptacie wa̧troby w powia̧zaniu ze średniodobowym stȩżeniem TGF-β1 w surowicy u chorych z przewlekłym zapaleniem wa̧troby typu B

Polskie Archiwum Medycyny Wewnetrznej

Volumn 114, Issue 2, 2005, Pages 738-745

  Marek, Bogdan ^a   Kajdaniuk, Dariusz ^a   Mazurek, Urszula ^b   Janczewska Kazek, Ewa ^c   Strzałka, Barbara ^b   Beniowski, Marek ^c   Kos Kudła, Beata ^d   Kajdaniuk, Joanna ^a   Niedziołka, Danuta ^d   Ostrowska, Zofia ^a   Borgiel Marek, Halina ^e   Siemińska, Lucyna ^a   Nowak, Mariusz ^a   Pakuła, Dorota ^f   Gatnar, Aleksander ^f   Gnot, Roman ^f   Filipczyk, Przemysław ^a  

^a Katedra Patofizjologii i Endokrynologii   (Poland)

^b la skiej Akademia Medyczna   (Poland)

^c AM   (Poland)

^d AM   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f Pracownia Medycyny Nuklearnej Szpitala Wojewódzkiego Nr 2   (Poland)

Author keywords

Chronic hepatitis B; Circadian rhythm; Liver fibrosis; mRNA; QRT PCR; TGF

Indexed keywords

MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CHRONIC HEPATITIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; PATIENT MONITORING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 33644785835     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gaynes R.P., Culver D.H., Horan T.C. i wsp.: Surgical site infection rates in the USA, 1992-1998: the National Nosocomial Infections Surveillance System basic SSI risk index. Clin. Infect. Dis., 2001, 33, 69.
2. Jurczyk K.: Leczenie przewlekłrych wirusowych zapaleń wa̧troby. Klinika, 1998, 11, 1133.
3. Wickert L., Abiaka M., Bolkenius U. i wsp.: Corticosteroids stimulate selectively transforming growth factor (TGF)-beta receptor type III expression in transdifferentiating hepatic stellate cells. J. Hepatol., 2004, 40, 69.
4. Olaso E., Friedman S. L.: Molecular mechanisms of hepatic fibrogenesis. J. Hepatol., 1998, 29, 836.
5. Bachem M.G., Riess U., Melchior R. i wsp.: Transforming growth factors (TGF alpha and TGF beta 1) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. FEBS Lett, 1989, 257, 134.
6. Gressner A.M.: Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J. Hepatol. 1995, 22, 28.
7. Bissel D. M., Wang S. S., Jarnagin W.R. i wsp.: Cell-specific expression of transforming growth factor-beta in rat liver. J. Clin. Invest., 1995, 96, 447.
8. Gressner A. M., Lotfi S., Gressner G. i wsp.: Synergism between hepatocytes and Kupffer cells in the activation of fat storing cells (perisinusoidal lipocytes). J. Hepatol., 1993, 19, 117.
9. Matsuoka M., Tsukamoto H.: Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor-beta: implication for a pathogenic role in alcoholic liver fibrogenesis. Hepatology, 1990, 11, 599.
10. Gabriel A., Ziólłkowski A.: New terminology of chronic hepatitis including scoring scale. Med. Sci. Monit, 1997, 3, 113.
11. Chomczyński P., Sacchi N.: Single-step method of RNA isolation by acid guanidinium-thiocyanate phenol-chloroform extraction. Anal. Biochem., 1987, 162, 156.
12. Derynck R., Jarrett J.A., Chen E.Y. i wsp.: Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature, 1985, 316, 701.
13. Ercolani R., Florence B., Denaro M.: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J. Biol. Chem., 1988, 263, 15335.
14. Halberg F, Tong Y.L, Johnson E.A.: Circadian system phase as aspect of temporal morphology: procedure and illustrative examples, [w:] Von Mayerbach H. editor. The cellular aspects of biorhythms, Springer-Verlag, Berlin, 1967, 1-12.
15. Marek B., Kajdaniuk D., Janczewska-Kazek E. i wsp.: Stȩżenia aminoterminalnego propeptydu prokolagenu typu III oraz transformuja̧cego czynnika wzrostu-betal we krwi obwodowej chorych z przewlekłym zapaleniem wa̧troby typu B i C. Pol. Arch. Med. Wew., 2003, 6, 603.
16. Kozłowska J., Loch T., Jabłońska J. i wsp.: Biochemiczne wykładniki włóknienia w przewlekłym zapaleniu wa̧troby i marskości watroby ïetiologii wirusowej. Przegł, Epidemiol, 2001, 55, 451.
17. Castilla A., Prieto J, Fausto N.: Transforming growth factors beta-1 and alpha in chronic liver disease. N. Engl. J. Med., 1991, 324, 933.
18. Annoni G., Weiner F.R., Zern M.A.: Increased transforming growth factor-betal gene expression in human liver disease. J. Hepatol., 1992, 14, 259.
19. Nelson D.R., Gonzales-Peralta R.P., Qian K. iwsp.: Transforming growth factor-betal in chronic hepatitis C. J. Vir. Hepat., 1997, 4, 29.
20. Bedossa P., Poynard T., Mathurin P. i wsp.: Transforming growth factor betal. In situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. Gut, 1993, 34, 146.
21. Roulot D., Durand H., Costs T. i wsp.: Quantitative analysis of transforming growth factor betal messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology, 1995, 21, 298.
22. Friedman S.C.: Liver-from bench to bedside. J. Hepatol., 2003, 38, 38.
23. Friedman S. L., Mäher J.J., Bissel D.M.: Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology, 2000, 32, 1403.
24. Dignass A. U., Podolsky D.K.: Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta-1. Gastroenterol., 1993, 105, 1323.
25. Fausto N.: Liver regeneration. J. Hepatol., 2000, 32 (suppl. 1), 19-31.
26. Grungreiff K., Reinhold D., Ansorge S.: Serum concentrations of sIL-2R, IL-6, TGF-betal, neopterin and zinc in chronic hepatitis C patients treated with interferon-alpha. Cytokine, 1999, 11, 1076.
27. Tsushima H., Kawata S., Tamura S. i wsp.: Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J. Hepatol., 1999, 30, 1.
28. Flisiak R., Pytel-Krolczuk B., Prokopowicz D.: Circulating transforming growth factor-beta1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine, 2000, 12, 677.
29. Santas R.M., Norton P., Eposti S.D. i wsp.: TGF-beta isoforms in alcoholic liver disease. J. Gastroenterol., 1998, 33, 383.
30. Kinnman A., Andersson U., Hulteranz R.: In situ expression of transforming growth factor-betal-3, latent transforming growth factor beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C. Scan. J. Gastroenterol., 2000, 35, 1294.
31. Neuman M., Angulo P., Malkiewicz I.M. i wsp.: Tumor necrosis-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J. Gastroenterol. Hepatol., 2002, 17, 196.
32. Shapiro S., Gershtein V., Elias N. i wsp.: mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus-infected patients: effects of interferon-alpha treatment. Clin. Exp. Immunol., 1998, 114, 55.